Literature DB >> 2320817

[Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].

P Pollak1, A S Champay, J M Gaio, M Hommel, A L Benabid, J Perret.   

Abstract

Apomorphine, a dopaminergic agonist was given over a period of 12 months to 14 parkinsonian patients suffering from severe L-dopa induced on-off effects. Nine patients (mean age: 52 years; mean age at onset of the disease: 37 years), were treated by continuous infusion with a portable minipump, and 5 others by multiple injections with a penject. The mean duration of daily off periods was reduced by two thirds in all patients. The motor fluctuation intensity was only diminished in the 9 patients treated by continuous infusion. These patients received a mean apomorphine daily dose of 93 mg and L-dopa dosage was reduced by 53 p. 100. Red fibrous subcutaneous nodules occurred at the injection sites in all patients treated by infusion. This study confirms the effectiveness of subcutaneous apomorphine administration in the treatment of severe motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320817

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  9 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

3.  Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.

Authors:  F Durif; E Jeanneau; F Serre-Debeauvais; D Deffond; A Eschalier; M Tournilhac
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Efficacy of sublingual apomorphine in Parkinson's disease.

Authors:  F Durif; D Deffond; M Tournilhac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

Review 5.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 6.  Role of apomorphine in the treatment of Parkinson's disease.

Authors:  Allison Boyle; William Ondo
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 7.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

8.  Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.

Authors:  D Deffond; F Durif; M Tournilhac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

Review 9.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.